Phase 1-2 trial of the BRAF inhibitor dabrafenib (D) plus MEK inhibitor trametinib (T) in BRAF V600 mutant colorectal cancer (CRC): Updated efficacy and biomarker analysis.
Year: 2014
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Ryan Bruce Corcoran, Chloe Evelyn Atreya, Gerald Steven Falchook, Jeffrey R. Infante, Omid Hamid, Wells A. Messersmith, Adil Daud, Eunice Lee Kwak, David Ryan, Razelle Kurzrock, Peng Sun, Elizabeth Ann Cunningham, Keith W. Orford, Monica Motwani, Yuchen Bai, Kiran Patel, Alan P. Venook, Scott Kopetz
Institutions: Massachusetts General Hospital, University of California, San Francisco, The University of Texas MD Anderson Cancer Center, Sarah Cannon, Tennessee Oncology, Angeles Clinic and Research Institute, University of Colorado Cancer Center, Harvard University, University of California San Diego, GlaxoSmithKline (United States), Thomas Jefferson University
Language: French
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2298065098